p. 1−13
2476-762X
Vol.13/No.1
p. 15−19
2476-762X
Vol.13/No.1
p. 21−25
2476-762X
Vol.13/No.1
p. 27−31
2476-762X
Vol.13/No.1
p. 33−35
2476-762X
Vol.13/No.1
p. 37−40
2476-762X
Vol.13/No.1
p. 41−48
2476-762X
Vol.13/No.1
p. 49−56
2476-762X
Vol.13/No.1
p. 57−62
2476-762X
Vol.13/No.1
p. 63−67
2476-762X
Vol.13/No.1
p. 69−73
2476-762X
Vol.13/No.1
p. 75−79
2476-762X
Vol.13/No.1
p. 81−85
2476-762X
Vol.13/No.1
p. 87−90
2476-762X
Vol.13/No.1
p. 91−96
2476-762X
Vol.13/No.1
p. 97−101
2476-762X
Vol.13/No.1
p. 103−110
2476-762X
Vol.13/No.1
C Polymorphism and Cancer Risk: A Metaanalysis]]>
C polymorphism with cancer risk have reportedconflicting results. To clarify the effect of the XRCC1 -77T>C polymorphism on cancer risk, we performeda meta-analysis by conducting searches of the published literature in PubMed, Embase and CBM databases.Finally, 13 studies were included into our meta-analysis, involving a total of 11, 678 individuals. Subgroupanalyses were performed by ethnicity and cancer type. The results of this meta-analysis showed that therewas significant association between the C variant of XRCC1-77T>C polymorphism and cancer risk in all fourgenetic comparison models (ORC vs. T =1.19, 95%CI 1.07-1.31, P = 0.001; OR homozygote model =1.28, 95%CI1.07-1.52, P = 0.007; OR recessive genetic model =1.22, 95%CI 1.04-1.44, P = 0.015; OR dominant model =1.21,95% CI 1.07-1.35, P = 0.001). In the subgroup analyses based on ethnicity, the association was still significantin the Asian population (all p values<0.001), but not in the Caucasian population (all p values > 0.05). Thus, theXRCC1 -77T>C polymorphism is associated with cancer risk, and individuals with XRCC1 -77C variant havea significantly higher cancer risk, particularly in the Asian population.]]>
p. 111−115
2476-762X
Vol.13/No.1
p. 117−122
2476-762X
Vol.13/No.1
p. 123−125
2476-762X
Vol.13/No.1
p. 127−130
2476-762X
Vol.13/No.1
p. 131−133
2476-762X
Vol.13/No.1
p. 135−138
2476-762X
Vol.13/No.1
p. 139−146
2476-762X
Vol.13/No.1
p. 147−155
2476-762X
Vol.13/No.1
p. 157−163
2476-762X
Vol.13/No.1
p. 165−168
2476-762X
Vol.13/No.1
p. 169−173
2476-762X
Vol.13/No.1
p. 175−179
2476-762X
Vol.13/No.1
p. 181−186
2476-762X
Vol.13/No.1
p. 187−190
2476-762X
Vol.13/No.1
p. 191−194
2476-762X
Vol.13/No.1
p. 195−198
2476-762X
Vol.13/No.1
p. 199−203
2476-762X
Vol.13/No.1
p. 205−209
2476-762X
Vol.13/No.1
p. 211−216
2476-762X
Vol.13/No.1
p. 217−220
2476-762X
Vol.13/No.1
p. 221−223
2476-762X
Vol.13/No.1
p. 225−229
2476-762X
Vol.13/No.1
p. 231−235
2476-762X
Vol.13/No.1
p. 237−241
2476-762X
Vol.13/No.1
p. 243−246
2476-762X
Vol.13/No.1
0.05). Conclusion: Ourresults suggest that ectopic expression of CDX2 and villin may be involved in early-stage IM and tumorigenesisin gastric cardia and the expression of villin may be regulated by CDX2.]]>
p. 247−250
2476-762X
Vol.13/No.1
p. 251−254
2476-762X
Vol.13/No.1
p. 255−260
2476-762X
Vol.13/No.1
p. 261−267
2476-762X
Vol.13/No.1
p. 269−273
2476-762X
Vol.13/No.1
20ng/ml(47%). Conclusion: High levels of CEA are associated with advanced stage of disease. CEA can thusprovide an important improvement in the diagnosis by differentiating pancreatic cancer especially from chronicpancreatitis when there is a high suspicion of malignancy. Increased CEA levels may also signify progressionfrom benign to malignant transformation in the liver.]]>
p. 275−277
2476-762X
Vol.13/No.1
p. 279−282
2476-762X
Vol.13/No.1
p. 283−287
2476-762X
Vol.13/No.1
p. 289−294
2476-762X
Vol.13/No.1
p. 295−300
2476-762X
Vol.13/No.1
0.05). Conclusions: Detecting TAM in NSCLC patients has a higher sensitivity and specificity,so it can be used as an indicator for clinical monitoring of lung cancer chemotherapy.]]>
p. 301−304
2476-762X
Vol.13/No.1
p. 305−308
2476-762X
Vol.13/No.1
p. 309−314
2476-762X
Vol.13/No.1
p. 315−318
2476-762X
Vol.13/No.1
p. 319−323
2476-762X
Vol.13/No.1
p. 325−328
2476-762X
Vol.13/No.1
p. 329−337
2476-762X
Vol.13/No.1
p. 339−342
2476-762X
Vol.13/No.1
p. 343−346
2476-762X
Vol.13/No.1
p. 347−350
2476-762X
Vol.13/No.1
p. 351−360
2476-762X
Vol.13/No.1
p. 361−365
2476-762X
Vol.13/No.1
50 years old. Conclusion: There is an increasing trend for breast cancer mortality in Iran. Thus, healtheducation programs to rectify the lack of women awareness about breast cancer signs and effective screeningare urgently needed.]]>
p. 367−370
2476-762X
Vol.13/No.1
p. 371−375
2476-762X
Vol.13/No.1
p. 377−381
2476-762X
Vol.13/No.1
p. 383−386
2476-762X
Vol.13/No.1
p. 387−390
2476-762X
Vol.13/No.1
p. 391−394
2476-762X
Vol.13/No.1
p. 395−398
2476-762X
Vol.13/No.1
p. 399−402
2476-762X
Vol.13/No.1
p. 403−406
2476-762X
Vol.13/No.1